WXXWY News and Press, Wuxi Biologics Cayman Inc ADR From 11/29/23

2023-11-29 17:57:54 ET Summary Ajinomoto is diversifying its revenue segments, particularly in the biopharma and semiconductor industries, for organic growth opportunities. The company has a leading market position, high R&D investment, and above-peer margins in the consumer s...

2023-11-26 02:40:00 ET Summary BeiGene acquires global rights to a preclinical CDK2 inhibitor from Ensem Therapeutics in a $1.3 billion agreement. Shanghai Usynova Biopharma out-licenses global rights for its KRASG12D inhibitor to AstraZeneca in a deal worth up to $419 million. ...

WuXi Biologics Successfully Implemented a Fully Integrated Continuous Process with a Breakthrough Productivity of ~6 g/L/day at Pilot Scale PR Newswire By leveraging WuXiUP TM , WuXi Biologics has completed its first end-to-end continuous drug substance (DS) manufacturing ...

WuXi Biologics Receives AAA MSCI ESG Rating PR Newswire SHANGHAI , Nov. 7, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has received an AAA rating ...

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality PR Newswire WuXiUI™ ultra-intensified fed-batch platform offers a new process option for maximum flexibilit...

2023-10-08 09:40:00 ET Summary Jiangsu QYuns Therapeutics has filed for a Hong Kong IPO to underwrite development of its portfolio of clinical-stage biologic antibody drugs for autoimmune and allergic diseases. Taiwan’s PharmaEssentia has acquired a myeloid immune checkpoin...

WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease PR Newswire WUXI, China , Oct. 1, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturi...

2023-09-08 00:03:09 ET Summary The recent IRA list of 10 drug publications is not expected to have a significant impact on big pharma stocks in the near term. The legal challenges by big pharma companies against the IRA may derail the implementation of the drug pricing reforms. ...

2023-07-19 06:49:45 ET Summary I have a favorable opinion of WuXi Biologics' planned spin-off, which could re-rate its valuations in a positive manner and help to accelerate the future growth of the spun-off business. WXXWY's disclosures at its recent Investor Day regarding new pr...

2023-07-19 05:32:00 ET Summary The drug outsourcing services company is spinning off its WuXi XDC unit, seizing on investor enthusiasm for a new generation of highly targeted ADC drugs. WuXi XDC has filed for a Hong Kong IPO, calling itself the world’s second largest provid...